Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;9(4):357-70.
doi: 10.1016/j.tranon.2016.05.004.

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies

Affiliations
Review

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies

Ana Rita Lima et al. Transl Oncol. 2016 Aug.

Abstract

Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death among men in Western countries. Current screening techniques are based on the measurement of serum prostate specific antigen (PSA) levels and digital rectal examination. A decisive diagnosis of PCa is based on prostate biopsies; however, this approach can lead to false-positive and false-negative results. Therefore, it is important to discover new biomarkers for the diagnosis of PCa, preferably noninvasive ones. Metabolomics is an approach that allows the analysis of the entire metabolic profile of a biological system. As neoplastic cells have a unique metabolic phenotype related to cancer development and progression, the identification of dysfunctional metabolic pathways using metabolomics can be used to discover cancer biomarkers and therapeutic targets. In this study, we review several metabolomics studies performed in prostatic fluid, blood plasma/serum, urine, tissues and immortalized cultured cell lines with the objective of discovering alterations in the metabolic phenotype of PCa and thus discovering new biomarkers for the diagnosis of PCa. Encouraging results using metabolomics have been reported for PCa, with sarcosine being one of the most promising biomarkers identified to date. However, the use of sarcosine as a PCa biomarker in the clinic remains a controversial issue within the scientific community. Beyond sarcosine, other metabolites are considered to be biomarkers for PCa, but they still need clinical validation. Despite the lack of metabolomics biomarkers reaching clinical practice, metabolomics proved to be a powerful tool in the discovery of new biomarkers for PCa detection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic illustration of the most significantly altered metabolic pathways in PCa cells. Dashed lines = downregulated pathway; continuous line = upregulated pathway. Metabolites overexpressed in PCa cells are shown in bold. TCA, tricarboxylic acid (cycle); AAs, amino acids; DNA, deoxyribonucleic acid; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; G6P, glucose-6-phosphate; 6P, 6-phosphate; 3PG, 3-phosphoglycerate; CoA, coenzyme A.

References

    1. Trock BJ. Application of metabolomics to prostate cancer. Urol Oncol. 2011;29:572–581. - PMC - PubMed
    1. Halama A. Metabolomics in cell culture—a strategy to study crucial metabolic pathways in cancer development and the response to treatment. Arch Biochem Biophys. 2014;564:100–109. - PubMed
    1. He JC, Chuang PY, Ma'ayan A, Iyengar R. Systems biology of kidney diseases. Kidney Int. 2012;81:22–39. - PMC - PubMed
    1. Ramautar R, Berger R, van der Greef J, Hankemeier T. Human metabolomics: strategies to understand biology. Curr Opin Chem Biol. 2013;17:841–846. - PubMed
    1. Monteiro M, Carvalho M, de Lourdes Bastos M, de Pinho P. Biomarkers in renal cell carcinoma: a metabolomics approach. Metabolomics. 2014;10:1210–1222.